ESR2 and thyroid cancer, nonmedullary, 2: Recently, ERβ has been reported to exhibit significantly higher expression in follicular thyroid adenoma than in follicular thyroid cancer (FTC), and to be a stronger differential diagnostic marker than Ki-67 [37].